



Trends in the availability and types of drugs sold on the internet via cryptomarkets, February 2025 - January 2026

Nicola Man, Rachel Sutherland, Monica J. Barratt, Raimondo Bruno, Vandit Sadaphale and Amy Peacock

This report was prepared by the National Drug and Alcohol Research Centre, UNSW Sydney


For further information: drugtrends@unsw.edu.au




From 1st February 2025 to 31st January 2026, 17 cryptomarkets were monitored, of which 13 remained active at the end of the reporting period.




The cryptomarkets reaching more than 10,000 listings in a snapshot during the 12-month period were Archetyp and Drughub.




There were 30,501 and 52,185 drug listings per snapshot in Feb 2025 and Jan 2026, respectively, with a non-significant trend of increase in listings of 1.7% per months.



These were the most frequently listed drugs making up >50% of the overall market from February 2025 to January 2026.



The market share of psychotropic medicines had the highest relative rate of increase from 2.0% in Feb 2025 to 2.8% in Jan 2026.



The greatest relative rate of decrease in market share was observed for GHB/GBL/1,4-BD from 0.5% in Feb 2025 to 0.4% in Jan 2026.

Key Findings

- From 1st February 2025 to 31st January 2026, 17 cryptomarkets were monitored, of which 13 remained active at the end of the reporting period.
- The two markets reaching more than 10,000 listings in a snapshot during this period were Archetyp and Drughub.
- In the final month of monitoring, Drughub, Dark Matter, Torzon, MarsMarket, Nexus and Blackops were the largest accessible cryptomarkets.
- Combined across monitored markets, there was 52,185 drug listings per snapshot in January 2026, with an estimated trend of increase in listings of 1.7% per month as compared to February 2025 (n=30,501) but the increase was not statistically significant.
- Cannabis comprised the greatest percentage of drug listings from February 2025 to January 2026 (25.3%). The other most frequently listed drugs making up 50% of the overall market were benzodiazepines (7.7%), MDMA (7.6%), opioids (excluding heroin) (7.3%) and cocaine (7.0%).
- The market share of other psychotropic medicines (e.g., gabapentin, bupropion) showed the highest relative rate of increase of 4.1% per month from 2.0% in February 2025 to 2.8% in January 2026. This is followed by other medicines (e.g., carisoprodol, promethazine) at 3.9% per month from 3.8% in February 2025 to 5.4% in January 2026. The increase in size of Drughub, Dark Matter and Blackops contributed to the increase in market share of these two drug classes as they have a proportionally bigger share of these drugs in their markets compared with the overall market.
- The greatest relative rate of decrease in market share of -4.0% per month was observed for GHB/GBL/1,4-BD from 0.5% in February 2025 to 0.4% in January 2026, and -1.5% per month for LSD, from 3.8% to 3.4%.

Figure 1. Word cloud of cryptomarkets monitored from February 2025 to January 2026 based on market size



Note: The maximum size of the market (in the period from 1st February 2025 to 31st January 2026 as shown in Table 1) is proportional to the font size of the cryptomarket. Abacus is not shown because we did not have a complete scrape within the 12-month period. The other four cryptomarkets that closed before the end of January 2026 is in grey colour font.

Table of Contents

KEY FINDINGS	2
BACKGROUND	6
Panel A. Terminology	7
FINDINGS	8
Profile of Cryptomarkets from February 2025 to January 2026	8
Which cryptomarkets were monitored during this period?	8
Which cryptomarkets closed during this period?	8
Which cryptomarkets from this period were the largest based on number of drug listings in a snapshot?	10
Size of Drug Market via Cryptomarkets from February 2025 to January 2026	11
Did the overall drug market size (based on number of drug listings in the monitored marketplaces) change over this period?	12
Did the market size of the main drugs available via cryptomarkets change over this period?	12
Market Share of Drugs Available via Cryptomarkets from February 2025 to January 2026	13
What were the main drugs available via cryptomarkets during this period?	13
Did the market share of the main drugs available via cryptomarkets change over this period?	16
Funding and Copyright	17
Recommended Citation	18
Acknowledgements	18
Related Links	18
Contact us	18

List of Figures

Figure 1. Word cloud of cryptomarkets monitored from February 2025 to January 2026 based on market size	3
Figure 2. Cryptomarkets monitored from February 2025 to January 2026.....	9
Figure 3. Number of drug listings by cryptomarkets with maximum of >1000 listings in a snapshot from February 2025 to January 2026.....	11
Figure 4. Number of listings disaggregated by drug class for the overall market from February 2025 to January 2026.....	Error! Bookmark not defined.

List of Tables

Table 1. Characteristics of cryptomarkets identified in this bulletin.	10
Table 2. Market size (number of listings) by drug class and their average monthly percent change (AMPC in %) from February 2025 to January 2026.....	12
Table 3. Market share (percentage of listings) [and rank of the most frequent listings making up 50% of each market] by drug class, by individual market and overall.....	15


Background



This bulletin series reports on trends in the availability and types of drugs sold on the internet via cryptomarkets over the last 12 months (a new bulletin is released typically every four months). The current bulletin focuses on analysis of drug listings on cryptomarkets from 1st February 2025 to 31st January 2026.

[Drug Trends](#) has identified, crawled (or 'scraped'), extracted, categorised and analysed drug listings on cryptomarkets on a regular basis since 1st January 2014, formerly using VBA programming processes, and since 9th August 2018 using a range of programmed automated processes in Python that operate with minimal manual input. Following extraction of common text features across each listing (e.g., drug listing name, vendor name), individual listings were then categorised according to a pre-specified drug classification structure. Drug categorisation is carried out through rules-based text-matching in the first instance, followed by a long short-term memory (LSTM) artificial neural network (target predictive percentage 90%) that had been trained on historically categorised listings for those not matched through the former process. Further background and information regarding the methods are available for [download](#).

Our reporting focuses on identified cryptomarkets which comply with the following: presented in English; have an accessible Tor link for scraping; have >1 vendor; vendors ship to and/or from Australia, or ship to and/or from multiple countries; and have had >100 drug listings (see the Methods document for more details).



An accompanying public [online interactive data visualisation](#) is available, allowing viewers to interact with data collected since February 2014. Data in the current bulletin and the accompanying interactive visualisation are presented as twice monthly snapshots before June 2025, and as monthly snapshots from June 2025 onwards. We present data on number of listings observed in a given snapshot

in the bulletin (see **Panel A**).

In this bulletin, we provide estimates of change over the 12-month reporting period by estimating average monthly percent change (AMPC) in number or proportion of listings per month using a generalised additive model (GAM) to account for non-linear trend, and a linear trend is fitted to compute the AMPC as detailed in the [Methods](#) document.

While these data can be considered reasonable estimates for trends in drug availability, we cannot guarantee exhaustive and/or immediate identification and capture of cryptomarkets once they emerge. As a result, there were some cryptomarkets which had existed for periods of time before our first scrape, resulting in a lack of data availability for these periods. In this bulletin, we show the date of the first post on a subDread.¹ for each monitored market to give an indication of when that market might have started (**Table 1**). There could also have been challenges in certain periods of time (e.g.,

¹ Dread is a forum on the darkweb that is analogous to Reddit. A subDread is a forum group on Dread. The administrators of a cryptomarket often open a subDread for their marketplace. However, the market may not yet be fully functional as there can be several months of web development, beta testing and onboarding of vendors before a market becomes fully operational. Thus, it is likely that monitored cryptomarkets reported on in this bulletin reached our eligibility criteria sometime between their first subDread post and our first scrape.

distributed denial of service (DDoS) attacks on sites) that prevented a routine scrape of an identified market.

Panel A. Terminology

- **Cryptomarkets** ('darknet markets') are online marketplaces that facilitate the purchasing of illicit goods and services via multiple sellers, and provide their users with anonymity via their location on the hidden web ([Barratt and Aldridge, 2016](#)). Our data collection and reporting focuses on drug listings advertised on cryptomarkets. A large proportion of listings are of prohibited drugs though licit drugs (e.g., alcohol, paracetamol) may occasionally be advertised on these platforms ([Christin and Thomas, 2019](#)).
- A **snapshot** of the cryptomarkets was taken on a twice monthly basis, in the two weeks starting on the 1st and 15th of each month before June 2025, and then on a monthly basis from June 2025 onwards.
- **Number of listings** is the sum of listings per snapshot belonging to a specific market and/or drug class. For this measure, duplicate listings (defined as listings with identical names by a single vendor on a single market within the same snapshot) are removed. Listings are further deduplicated for quantity variants (see **section 5.2.1** in the [Methods](#) document).
- **Market size** is defined as the number of drug listings per snapshot, overall, by market or by drug class.
- **Market share** is defined as the percentage of total drug listings by drug class.
- **Average monthly percent change (AMPC)** is the relative percent change in number or percentage of listings per month fitted as a Poisson variable in a generalised additive model using the [mgcv](#) package in R.

Since our findings do not reflect the total of all cryptomarkets existing in the reporting period, the analysis and estimates in this bulletin should not be used to infer the number of drug listings across all cryptomarkets. Further, they should only be considered a proxy indicator of drug availability: we have not provided any metric that reflects sales or purchasing of drugs via cryptomarkets. See [here](#) for further discussion of caveats to interpretation.

There are various approaches to collecting, collating, categorising and analysing cryptomarket data, and inherent challenges in these processes. Our monitoring is an ongoing process. Refinements to our reporting processes in each bulletin are reported in the accompanying methods document. We welcome feedback and suggestions so that we can continue to improve utility of these data and our reporting on them (contact us at drugtrends@unsw.edu.au).

Findings

Profile of Cryptomarkets from February 2025 to January 2026

Which cryptomarkets were monitored during this period?



The current bulletin reports findings for the time period 1st February 2025 to 31st January 2026 ([Figure 2](#)). In the current monitoring period, 17 cryptomarkets were monitored. [Table 1](#) shows the characteristics of these cryptomarkets since the date of our first scrape. Scraped data might be missing for some markets in certain periods (see [Figure 2](#)). In particular, we note that the last complete scrape for Abacus was in the 15th November 2024 snapshot because the frequency of CAPTCHA was too labour-intensive for regular scraping. For this reason, Abacus is excluded from the analyses in this bulletin. It closed in the beginning of July 2025 and we last accessed Abacus for a collection of Australian-origin listings in the 1st April 2025 snapshot. It is only presented in [Table 1](#) which do not quantify trend in the number or proportion of listings over time.

Which cryptomarkets closed during this period?




Of the 17 markets monitored (excluding Abacus) in this bulletin, 4 cryptomarkets (33% of the monitored markets) closed within the reporting period for the following purported reasons ([Table 1](#)):

- Quantum closed for unknown reasons. It had been monitored for 11.5 months from the 15th March 2024 to the 15th February 2025 snapshot;
- Archetyp is considered to have [closed](#) from law enforcement seizure in June 2025. It had been monitored for 40.5 months from the 15th January 2022 to the 15th May 2025 snapshot;
- MGM Grand is considered to have closed with a voluntary exit announced on its subDread. It had been monitored for 37.5 months from the 15th May 2022 to the 1st June 2025 snapshot; and
- Elysium is considered to have closed. Its subDread was deleted and an exit scam or law enforcement evasion were suspected. It had been monitored for 16 months from the 1st March 2024 to the 1st June 2025 snapshot.

Abacus is also considered to have [closed](#) from an exit scam in [early July 2025](#). It had been monitored for 38 months from the 15th February 2022 to the 1st April 2025 snapshot.

Figure 2. Cryptomarkets monitored from February 2025 to January 2026.

Source: DrugTrends, NDARC



Note: There are short breaks at the end of each month because the twice-monthly snapshots before June 2025 were based on 2-week intervals starting on the 1st and 15th of each month, and the snapshots were taken at monthly intervals from June 2025 onwards at a time between the 1st and the 28th of the month, i.e., days of the month after the 28th were excluded from monitoring. Extended breaks indicate periods where market crawling was not achievable or incomplete. The height of the bar is proportional to the log of the number of drug listings observed in each snapshot for each market.

The other 13 markets remained active at the end of the 12-month period (Table 1).

Table 1. Characteristics of cryptomarkets identified in this bulletin.

Market	Status as of Jan 2026 (reported reason ^a)	Earliest subDread post	First snapshot	Last snapshot	Duration in months ^b	Maximum number of listings ^c
Archetyp	<u>Closed</u> (law enforcement)	19 th Apr 2020	15 th Jan 2022	15 th May 2025	40.5	13,424
Abacus	<u>Closed</u> (exit scam)	27 th Sep 2020	15 th Feb 2022	1 st Apr 2025 ^d	38	--
MGM Grand	<u>Closed</u> (voluntary exit)	26 th Apr 2021	15 th May 2022	1 st Jun 2025	37.5	3,630
Ares	Open	26 th Aug 2021	15 th May 2022	Ongoing ^e	44.5*	1,856
Colombia Connection	Open	3 rd Nov 2020	15 th Jul 2022	Ongoing ^e	42.5*	279
Dark Matter	Open	22 nd Sep 2022	15 th Mar 2023	Ongoing ^e	34.5*	9,228
Torzon	Open	15 th Nov 2022	15 th Nov 2023	Ongoing ^e	26.5*	7,755
Elysium	<u>Closed</u> (exit scam)	28 th Jun 2023	1 st Mar 2024	1 st Jun 2025	16	1,943
Nexus	Open	5 th Jan 2024	1 st Mar 2024	Ongoing ^e	23*	5,595
Quantum	Closed (unknown)	-- ^f	15 th Mar 2024	15 th Feb 2025	11.5	619
Vortex	Open	28 th Nov 2023	15 th Apr 2024	Ongoing ^e	21.5*	1,454
Euphoria	Open	18 th Apr 2024	15 th Apr 2024	Ongoing ^e	21.5*	380
Drughub	Open	17 th Aug 2023	1 st Mar 2025	Ongoing ^e	11*	12,898
Blackops	Open	21 st Sep 2024	1 st Mar 2025	Ongoing ^e	11*	5,295
MarsMarket	Open	12 th Jan 2025	1 st Mar 2025	Ongoing ^e	11*	5,678
Atlas	Open	7 th Dec 2023	1 st Jan 2026	Ongoing ^e	1*	870
Canna Express	Open	4 th Oct 2024	1 st Jan 2026	Ongoing ^e	1*	617
Prime	Open	4 th Mar 2025	1 st Jan 2026	Ongoing ^e	1*	1,506

Note: The cell for the markets that closed during the 12-month period are greyed out. Markets are ordered by date of first snapshot, then date of earliest subDread post. ^a Most probable reason for closure is given in brackets. ^b Duration of monitoring is the number of months between the start of the first snapshot and the end of the last snapshot, including when data could not be scraped from the cryptomarket. Where the cryptomarket was still active and monitored as of 31st January 2026 (indicated by *), the duration was computed as the number of months between the first snapshot and 31st January 2026. ^c Maximum number of listings in a scrape was computed from the snapshots over the 12-month reporting period. ^d Abacus was last accessed in the 1st April 2025 snapshot for a collection of Australian-origin listings (see [Which cryptomarkets were monitored during this period?](#) for details). ^e The cryptomarket was active as of 31st January 2026. ^f Quantum's subDread could not be found on Dread.

Which cryptomarkets from this period were the largest based on number of drug listings in a snapshot?



The markets reaching more than 10,000 listings in a snapshot during the 12-month period ([Table 1](#) and [Figure 3](#)) were:


- Archetyp with maximum number of listings in a snapshot of 13,424; and
- Drughub with maximum number of listings in a snapshot of 12,898.

The smallest of the scraped cryptomarkets with a maximum of less than 1,000 listings per snapshot were ColombiaConnection, Euphoria, CannaExpress, Quantum and Atlas (**Table 1**).

In the final month of monitoring (January 2026), 13 markets were scraped. The six markets whose number of listings were above the average of 4,014 listings in January 2026 were (**Figure 3**):

- Drughub with 12,818 listings;
- Dark Matter with 9,030 listings;
- Torzon with 7,755 listings;
- MarsMarket with 5,678 listings;
- Nexus with 5,595 listings; and
- Blackops with 5,006 listings.

Figure 3. Number of drug listings by cryptomarkets with minimum of >1000 listings in a snapshot from February 2025 to January 2026.



Note: Markets with <1000 listings in a snapshot across the whole 12-month period (i.e., ColombiaConnection, Euphoria, CannaExpress, Quantum and Atlas) were excluded to improve visibility. Complete interactive visualisation available [here](#). The markets are ordered by maximum number of listings per snapshot over the 12-month period as shown in **Table 1**.

Size of Drug Market via Cryptomarkets from February 2025 to January 2026

Market listings captured through cryptomarket monitoring have been identified and categorised into 25 main drug classes at Level 2 as described in our [methodology](#). Number of cryptomarket listings of specific drugs belonging under these drug classes are shown in our data visualisation (e.g., [benzodiazepines at Level 1](#)).

Did the overall drug market size (based on number of drug listings in the monitored marketplaces) change over this period?

There were 30,501 and 52,185 drug listings per snapshot in February 2025 and January 2026, respectively, with an estimated increase in listings of 1.7% per month during the [12-month period](#) but the increase was not statistically significant ([Table 2](#)).

Did the market size of the main drugs available via cryptomarkets change over this period?

The drugs below had a significant increase in number of listings ([Table 2](#)):

- Other psychotropic medicines from 624 to 1,449 listings (5.9% per month); and
- Other medicines from 1,171 to 2,796 listings (5.7% per month).

Table 2. Market size (number of listings) by drug class and their average monthly percent change (AMPC in %) from February 2025 to January 2026.

Drug	Market size (Mean number of listings) ^a			Average monthly percent change (AMPC) ^b	
	Overall	Feb 2025	Jan 2026	AMPC (95%CI)	P-value
Cannabis	9755	8226	13878	1.6 (-2.8, 6.1)	0.482
Benzodiazepines	2982	2377	3436	0.7 (-2.4, 3.8)	0.665
MDMA	2939	2414	3731	0.5 (-3.2, 4.3)	0.804
Opioids (excluding heroin)	2804	2170	3353	1.9 (-1.1, 5.1)	0.209
Cocaine	2700	2152	3534	1.4 (-1.6, 4.5)	0.352
PIEDs/weight loss drugs^c	2548	1668	3803	3.8 (-0.5, 8.2)	0.077
Meth/amphetamine (illicit)	2158	1812	2684	0.2 (-2.5, 3.1)	0.864
Ketamine	2010	1558	2816	2.4 (-1.8, 6.8)	0.253
NPS	1967	1481	2642	1.9 (-1.6, 5.4)	0.283
Other medicines^d	1762	1171	2796	5.7 (1.9, 9.7)*	0.002
Other psychostimulants & nootropics	1482	1142	1957	2.4 (-0.5, 5.5)	0.103
LSD	1326	1152	1791	-1.7 (-5.6, 2.4)	0.406
Hallucinogenic mushrooms	960	798	1465	1.5 (-2.0, 5.2)	0.398
Other psychotropic medicines^e	936	624	1449	5.9 (2.3, 9.6)*	<0.001
Heroin	785	580	1089	2.5 (-0.9, 6.0)	0.149
Other drugs	543	465	642	0.1 (-3.3, 3.7)	0.935
DMT	456	386	559	-1.1 (-4.8, 2.7)	0.547
GHB/GBL/1,4-BD	196	150	212	-2.5 (-6.1, 1.2)	0.177
Total^f	38551	30501	52185	1.7 (-1.8, 5.4)	0.330

Note: ^a This shows the mean number of listings per snapshot across all marketplaces observed in the stated period. ^b Average monthly percent change (AMPC) in market size is the estimated relative percent change in number of listings of the particular drug per month. The estimates that are statistically significant at $p < 0.05$ are marked with "*" and highlighted in bold. ^c PIEDs: performance and image enhancing drugs. Please refer to our [interactive visualisation](#) for examples. ^d These are all other medicines not in other categories of drugs. Please refer to our [interactive visualisation](#) for examples. ^e These are pharmaceutical drugs with psychotropic effects excluding drugs already in other categories of drugs, e.g. psychostimulants and opioids which are in their specific classes of 'other psychostimulants & nootropics' and 'opioids (excluding heroin)', respectively. Please refer to our [interactive visualisation](#) for examples. ^f The 'Total' row comprises all drug listings

including those not shown in this table due to small values, i.e. alcohol, e-cigarette, inhalants, MDA, paraphernalia, PCP and tobacco, with each constituting <0.5% of the overall market share.


Market Share of Drugs Available via Cryptomarkets from February 2025 to January 2026

What were the main drugs available via cryptomarkets during this period?

Cannabis comprised the largest proportion of listings identified across the overall market over the 12-month period (25.3%) (see last row in **Table 3** and last column in **Figure 4**). The other most frequently listed drugs making up at least 50% of listings in the overall market were:

- benzodiazepines, with 7.7% of listings;
- MDMA, with 7.6% of listings;
- opioids (excluding heroin), with 7.3% of listings; and
- cocaine, with 7.0% of listings.

Figure 4. Drug market share by individual market and overall.



New psychoactive substances (NPS) comprised 5.1% of listings. The categorisation framework has recently been updated to incorporate additional drug terms, including terms for nitazenes (see Man

et al., 2024; Man et al., 2025), other novel opioids and benzodiazepines, synthetic cannabinoid receptor agonists (e.g., gidazepam), and pharmaceutical brand names (e.g., Wellbutrin). Yet, some drug categories, and particularly NPS, may still be underestimated. Further details on categorisation of listings are in the accompanying methods bulletin. We will continue to update the drug terms as new drugs emerge.

Cannabis was also the most frequently listed drug across all cryptomarkets (**Table 3**). This was followed by:

- benzodiazepines for Nexus (9.2%), Dark Matter (8.7%) and Atlas (8.5%);
- MDMA for MarsMarket (11.1%) and Archetyp (8.6%);
- Opioids (excluding heroin) for ColombiaConnection (23.0%), Euphoria (17.4%), Prime (10.9%), Vortex (10.7%), and MGM Grand (10.2%);
- Cocaine for Ares (9.8%), Torzon (8.3%) and Elysium (9.1%);
- PIEDs/weight loss drugs for Blackops (10.3%) and Drughub (9.4%); and
- Meth/amphetamine (illicit) for Quantum (11.0%).

The market share of drugs in the individual markets with a significant relative difference of 50% or more compared with all other markets are underlined and in bold in **Table 3**. The following drugs had significantly bigger market share primarily in the smallest markets with a maximum of less than 1000 listings in a snapshot (i.e., ColombiaConnection, Euphoria, CannaExpress, Quantum and Atlas):

- Cannabis in CannaExpress had a market share of 95.5% compared to 25.3% in the overall market.
- Opioids (excluding heroin) in ColombiaConnection and Euphoria had market share of 23.0% and 17.4%, respectively, compared to 7.3% in the overall market.
- Meth/amphetamines (illicit) in Quantum with market share of 11.0% compared to 5.6% in the overall market.
- Other psychostimulants and nootropics in ColombiaConnection with market share of 7.4% compared to 3.8% in the overall market.
- Hallucinogenic mushrooms in Atlas and Quantum had market share of 5.3% and 4.3%, respectively, compared to 2.5% in the overall market.

This suggests that some of these smaller markets (e.g., CannaExpress) could be niche markets for particular drugs or market segment.

Table 3. Market share (percentage of listings) [and rank of the most frequent listings making up 50% of each market] by drug class, by individual market and overall.

Market	Cannabis	Benzo-diazepines	MDMA	Opioids (excluding heroin)	Cocaine	PIEDs/weight loss drugs	Meth/amphetamine (illicit)	Ketamine	NPS	Other medicines	Other psycho-stimulants & nootropics	LSD	Hallucinogenic mushrooms	Other psychotropic medicines	Heroin	DMT	GHB/GBL/1,4-BD
Archetyp (81408)	[1] 28.8**	[4] 6.8	[2] 8.6**	5.8	[3] 7.4**	5.3	5.5	5.6**	5.7**	2.9	3.5	3.3	3.1**	1.8	1.6	1.0	0.5
Drughub (114727)	[1] 25.8**	[3.5] 7.1	[5] 6.4	5.7	6.0	<u>[2] 9.4**</u>	4.4	4.4	4.9	<u>[3.5] 7.1**</u>	4.1**	3.0	2.5	<u>4.0**</u>	1.5	1.1	0.4
Dark Matter (94302)	[1] 25.0	[2] 8.7**	[4] 6.8	[5.5] 6.3	6.3	[3] 7.5**	4.4	4.6	5.8**	6.2**	4.1**	3.2	2.7**	3.3**	1.8	1.0	0.3
Torzon (74192)	[1] 28.9**	5.3	6.9	[3.5] 7.4	[2] 8.3**	5.3	[3.5] 7.4**	5.8**	4.9	3.6	3.3	3.6*	2.8**	1.5	2.1	1.3	0.4
Nexus (78865)	[1] 22.8	[2] 9.2**	[3] 7.7	[4] 7.6**	6.2	[5] 6.7	5.8	5.3	4.9	5.3**	3.8	3.5	2.0	3.1**	2.1	1.2	0.5
MGM Grand (32127)	[1] 28.1**	[3] 8.5**	6.7	[2] 10.2**	[4] 6.9	5.9	5.1	4.5	3.6	2.9	4.4**	3.6	2.6	1.6	1.4	<u>2.1**</u>	0.5
Blackops (41669)	[1] 22.3	[4] 8.9**	[3] 9.2**	7.1	5.8	<u>[2] 10.3**</u>	5.6	6.3**	5.8**	3.2	3.1	3.4	1.9	1.2	2.8**	1.0	<u>0.8**</u>
MarsMarket (35545)	[1] 21.8	[4] 9.0**	[2] 11.1**	[3] 10.0**	8.6**	1.1	7.8**	7.2**	6.3**	1.2	4.2**	2.7	1.6	0.8	2.8**	1.0	<u>1.0**</u>
Elysium (14856)	[1] 20.1	6.9	[4] 7.3	[3] 7.4	[2] 9.1**	3.5	[5] 7.1**	5.5	6.9**	4.2	5.3**	<u>5.8**</u>	1.9	1.0	2.5**	<u>2.3**</u>	<u>1.1**</u>
Prime (1506)	[1] 21.3	5.9	[4] 9.2	[2] 10.9**	8.2	[3] 9.6**	6.5	4.8	4.3	1.9	3.4	4.9*	2.7	0.6	2.7	1.4	0.6
Ares (20705)	[1] 22.8	[4] 7.7	[3] 8.9**	[5] 7.4	[2] 9.8**	7.3**	6.6**	4.4	2.3	2.8	3.5	3.5	2.8*	1.5	<u>4.9**</u>	1.5**	0.6*
Vortex (16012)	[1] 18.4	[4] 9.9**	[3] 10.5**	[2] 10.7**	[5] 8.4**	3.6	5.4	6.2**	3.3	3.6	3.9	<u>5.3**</u>	2.0	2.3	2.4**	1.4	<u>0.8**</u>
Atlas (870)	[1] 34.5**	[2] 8.5	[3] 7.0	5.7	5.9	1.5	3.7	3.1	2.8	6.4	4.0	4.7	<u>5.3**</u>	3.4	1.4	0.7	0.3
CannaExpress (617)	[1] <u>95.5**</u>	–	1.0	–	0.2	–	–	–	0.2	–	–	–	0.3	–	–	–	–
Quantum (1123)	[1] 19.2	8.4	9.1	[3] 10.7**	[4] 10.2**	5.4	<u>[2] 11.0**</u>	1.8	2.9	1.8	4.1	4.5	<u>4.3**</u>	0.9	2.1	0.7	<u>1.8**</u>
Euphoria (4189)	[1] 20.9	[4] 8.3	1.4	<u>[2] 17.4**</u>	[3] 9.3**	0.3	7.3**	1.1	3.8	4.2	4.1	<u>7.6**</u>	3.7**	2.8	1.4	1.0	–
ColombiaConnection (4108)	[1] 25.2	5.5	2.6	<u>[2] 23.0**</u>	6.6	0.0	3.9	5.0	2.7	6.2**	<u>[3] 7.4**</u>	<u>5.7**</u>	1.9	0.4	1.9	0.4	–
OVERALL (616821)	[1] 25.3	[2] 7.7	[3] 7.6	[4] 7.3	[5] 7.0	6.6	5.6	5.2	5.1	4.6	3.8	3.4	2.5	2.4	2.0	1.2	0.5

Note: The markets are sorted in descending order by their maximum number of listings in the 12-month period in **Table 1**, with the overall market shown in the last row. The total number of listings over the 12-month period are shown in brackets next to each market name. The cell for the markets that closed during the 12-month period are greyed out. Each column is colour coded to highlight the markets with the lowest percentage of listings of the drug in green, the mid-range percentages in yellow and the markets with the highest percentages in purple, following the colour scale range. The rank of the most frequent listings making up 50% of each market and the overall market are shown in square brackets. The drugs in individual markets that had a significantly higher percentage of the drug compared with all other markets are indicated with * ($p < 0.01$) and ** ($p < 0.001$). The estimated individual market share of drugs with a significant relative difference of 50% or higher compared with all other markets are underlined and in bold.

The following drugs also had significantly bigger market share in various individual markets:

- PIEDs/weight loss drugs in Blackops and Drughub had market share of 10.3% and 9.4%, respectively, compared to 6.6% in the overall market.
- Other medicines and other psychotropic medicines with market share of 7.1% and 4.0%, respectively, in Drughub compared to 4.6% and 2.4%, respectively, in the overall market.
- LSD in Euphoria (7.6%), Elysium (5.8%), ColombiaConnection (5.7%) and Vortex (5.3%) compared to the overall market (3.8% market share).
- Heroin in Ares with market share of 4.9% compared to the overall market share of 2.0%.
- DMT in Elysium (2.3%) and MGM Grand (2.1%) both of which already closed, compared to the overall market (1.2%).
- GHB/GBL/1,4-BD in Quantum (1.8%), Elysium (1.1%), MarsMarket (1.0%), Blackops and Vortex (both 0.8%), compared to the overall market (0.5% market share).

Did the market share of the main drugs available via cryptomarkets change over this period?

Other psychotropic medicines had the greatest rate of relative increase in market share (4.1% per month) from February 2025 to January 2026 (2.0% of all drug listings to 2.8%, respectively; **Table 4** and **Figure 5**). This was followed by:

- other medicines increasing at 3.9% per month, from 3.8% to 5.4%;
- PIEDs/weight loss drugs increasing at 2.0% per month, from 5.4% to 7.3%;
- heroin increasing at 0.7% per month, from 1.9% to 2.1%; and
- ketamine increasing at 0.6% per month, from 5.1% to 5.4%.

The increase in size of Drughub, Dark Matter and Blackops (following the closure of Archetyp) may have contributed to the increase in market share of other psychotropic medicines, other medicines and PIEDs/weight loss drugs as they have a proportionally bigger share of these drugs in their markets compared with the overall market (see **Table 3**).

Specific drugs under other psychotropic medicines that had a significant increase in number and proportion of listings include gabapentin and bupropion. Examples of other medicines that had a significant increase in number and proportion of listings include carisoprodol, promethazine and propranolol.

GHB/GBL/1,4-BD had the greatest relative decrease in market share (-4.0% per month) from 0.5% in February 2025 to 0.4% in January 2026. This was followed by LSD (-3.3% per month) from February 2025 to January 2026 (3.8% of all drug listings to 3.4%, respectively; **Table 4**). The following drugs also decreased significantly in market share:

- meth/amphetamine (illicit) decreasing at -1.5% per month, from 5.9% to 5.1%;
- MDMA decreasing at -1.3% per month, from 7.9% to 7.1%; and
- benzodiazepines decreasing at -1.1% per month, from 7.8% to 6.6%.

Specific drugs under benzodiazepines that had a significant decrease in proportion of listings include alprazolam, clonazepam and zolpidem.

Table 4. Market share (percentage of listings) by drug class in February 2025 and January 2026, and their average monthly percent change (AMPC in %) from February 2025 to January 2026.

Drug	Market share (percentage of listings) ^a		Average monthly percent change (AMPC) ^b	
	Feb 2025	Jan 2026	AMPC (95%CI)	P-value
Cannabis	26.9	26.6	-0.2 (-1.2, 0.8)	0.723
Benzodiazepines	7.8	6.6	-1.1 (-1.8, -0.3)*	0.003
MDMA	7.9	7.1	-1.3 (-1.7, -0.8)*	<0.001
Opioids (excluding heroin)	7.1	6.4	0.2 (-1.4, 1.8)	0.802
Cocaine	7.1	6.8	-0.3 (-1.1, 0.5)	0.424
PIEDs/weight loss drugs^c	5.4	7.3	2.0 (0.7, 3.3)*	0.001
Meth/amphetamine (illicit)	5.9	5.1	-1.5 (-2.4, -0.5)*	0.002
Ketamine	5.1	5.4	0.6 (0.1, 1.2)*	0.028
NPS	4.9	5.1	0.1 (-0.5, 0.7)	0.699
Other medicines^d	3.8	5.4	3.9 (2.6, 5.2)*	<0.001
Other psychostimulants & nootropics	3.8	3.8	0.7 (-0.1, 1.4)	0.079
LSD	3.8	3.4	-3.3 (-5.6, -1.0)*	0.004
Hallucinogenic mushrooms	2.6	2.8	-0.2 (-1.9, 1.5)	0.809
Other psychotropic medicines^e	2.0	2.8	4.1 (2.7, 5.4)*	<0.001
Heroin	1.9	2.1	0.7 (0.0, 1.5)*	0.034
Other drugs	1.5	1.2	-1.6 (-2.4, -0.9)*	<0.001
DMT	1.3	1.1	-2.8 (-5.1, -0.4)*	0.019
GHB/GBL/1,4-BD	0.5	0.4	-4.0 (-5.7, -2.2)*	<0.001
Total^f	100.0	100.0	--	--

Note: ^a Market share is the number of listings of the drug as a percentage of the number of all drug listings per snapshot across all marketplaces observed in the stated period. ^b Average monthly percent change (AMPC) in market share is the estimated relative percent change in percentage of listings of the particular drug per month. The estimates that are statistically significant at $p < 0.05$ are marked with "*" and highlighted in bold. See [methods](#) for further details. ^c PIEDs: performance and image enhancing drugs. Please refer to our [interactive visualisation](#) for examples. ^d These are all other medicines not in other categories of drugs. Please refer to our [interactive visualisation](#) for examples. ^e These are pharmaceutical drugs with psychotropic effects excluding drugs already in other categories of drugs, e.g. psychostimulants and opioids which are in their specific classes of 'other psychostimulants & nootropics' and 'opioids (excluding heroin)', respectively. Please refer to our [interactive visualisation](#) for examples. ^f The 'Total' row comprises all drug listings including those not shown in this table due to small values, i.e. alcohol, e-cigarette, inhalants, MDA, paraphernalia, PCP and tobacco, with each constituting <0.5% of the overall market share.

Funding and Copyright

Funded by the Australian Government Department of Health, Disability and Ageing under the Drug and Alcohol Program ©NDARC, UNSW SYDNEY 2026. This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, NDARC, UNSW Sydney, NSW 2052, Australia via drugtrends@unsw.edu.au.

Recommended Citation

Man, N., Sutherland, R., Barratt, M. J., Bruno, R., Sadaphale, V., & Peacock, A. (2026). [Trends in the availability and type of drugs sold on the internet via cryptomarkets, February 2025 - January 2026](https://doi.org/10.26190/unsworks/32119). Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Available from: <https://doi.org/10.26190/unsworks/32119>

Acknowledgements

We would like to acknowledge the following individuals for their contribution to this project: Dr Anant Mathur, Max Pedersen, Rajat Katyal, Dr Qingyuan Linghu, Yang Yan, Agata Chrzanowska, Dr Amanda Roxburgh, Joe van Buskirk, A/Prof Timothy Dobbins, A/Prof Lucinda Burns, Dr Courtney Breen, Sundresan Naicker and Rosie Swanton.

Related Links

- Data visualisations: <https://drugtrends.shinyapps.io/cryptomarkets>
- For more research from the Drug Trends program go to: <https://www.unsw.edu.au/research/ndarc/research-impact/research-areas/drug-trends>

Contact us

Email: drugtrends@unsw.edu.au